Patient Perspective on Cross-Linking

Learn more about the importance of early diagnosis and treatment from a keratoconus patient and her treating physician.

A General Overview

Corneal cross-linking is a minimally invasive outpatient procedure that combines the use of Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® system for the treatment of progressive keratoconus.

Corneal Cross-Linking:
  • Creates new corneal collagen cross-links
  • Results in a shortening and thickening of the collagen fibrils
  • Leads to the stiffening of the cornea

Top Questions to Ask Your Eye Doctor Download PDF

FDA Approval

The first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus.

In April 2016, the FDA approved Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® System for corneal cross-linking, a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light.

The approval of Photrexa Viscous, Photrexa and the KXL System offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.

Cross-Linking

Learn more about this outpatient procedure

View our Living with Keratoconus Patient Brochure.

Patient FAQs

Discover answers to the most common questions surrounding cross-linking

Visit the Patient FAQ Section to learn more.

It is estimated that...

1 Out of Every 2,000

persons in the general population have Keratoconus1

You can find more information from the National Keratoconus Foundation.

1. Kennedy R. H., Bourne W. M., Dyer J. A. A 48-year clinical and epidemiologic study of keratoconus. The American Journal of Ophthalmology. 1986;101(3):267–273. doi: 10.1016/0002-9394(86)90817-2.

Corneal cross-linking provides patients a much-needed option to treat this debilitating disease. Patients suffering from progressive keratoconus can now receive a therapeutic treatment that has been rigorously tested and approved."

Mary Prudden, Executive Director for the National Keratoconus Foundation

What are Patients Saying? View Stories

Learn More Through Our Facebook Page

Looking for a physician offering FDA-apporved #crosslinking? Dr. Iuorno @CommonwealthEyeCare Associates offers some tips! ... See MoreSee Less

View on Facebook

The number of insurance companies covering #crosslinking continues to increase. Visit our website to see the growing coverage trend from January 2017 to today! ... See MoreSee Less

View on Facebook

Learn More Through Our Twitter Page

Looking for a physician offering FDA-approved #crosslinking? #KCExpert Dr. Iuorno @CommonwealthECA offers some tips!

The number of insurance companies covering #crosslinking continues to increase. Visit our website to see the growing coverage trend from January 2017 to today!

The last #KCFamilySymposium of 2018 is this weekend! For details on this event and highlights from past symposiums, read our latest blog: https://t.co/sNa2ki4siE

Have you seen our #KCExpert Q&A’s? Each week we highlight a #keratoconus expert who provides insights into common KC questions

Epi-off, Epi-on, C3R - Which are covered by insurance? Our blog clears up any confusion https://t.co/q5p04x3Eko

Load More...

Learn More Through Our Instagram

MA-00687B